NEW YORK (360Dx) – Mologic and PATH said today that they have entered an agreement to advance a new rapid diagnostic test (RDT) to support treating and eliminating Plasmodium vivax malaria.
PATH, an international nonprofit with a focus on improving health, especially among women and children, is supporting Mologic in commercializing the RDT and obtaining regulatory approvals.
Financial and other terms of the agreement were not disclosed.